The main research areas of the group are:

• molecular basis of onset and reversion of chemoresistance in human tumors;
• molecular basis of onset and reversion of immune-resistance/immune-evasion in human tumors
• synthesis and validation of new combinatorial antitumor therapies (e.g. multitarget drugs; nanoparticles-based chemotherapy; chemo-immunotherapy approaches).